Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adicet Bio Inc
(NQ:
ACET
)
2.100
UNCHANGED
Streaming Delayed Price
Updated: 4:15 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Adicet Bio Inc
< Previous
1
2
3
Next >
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
April 22, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
April 08, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
March 19, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 11, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
February 29, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
January 31, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
January 25, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio, Inc. Announces Pricing of Public Offering
January 22, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio, Inc. Announces Proposed Public Offering
January 22, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024
January 04, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook
January 03, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
December 29, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting
December 10, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 08, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference
November 07, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting
November 02, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
October 31, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference
October 04, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
September 27, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 31, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 09, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 31, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Announces Appointment of Katie Peng to the Board of Directors
July 11, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 30, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
June 26, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference
June 01, 2023
From
Adicet Bio, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.